Forbes1y
FDA Approved A New Weight Loss Drug Zepbound. Here’s What To Know And Expect
Opinions expressed by Forbes Contributors are their own. Dr. Omer Awan is a practicing physician who covers public health. CARLSBAD, CA-NOV 30TH: Mounjaro injection pen on display at Rachel Graham ...
MarketWatch26d
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had ...
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...